Portfolio of Cancer Immunotherapy Stocks
Here are 23 cancer immunotherapy stocks.
|23 Cancer Immunotherapy Stocks|
Stock Returns & Price Chart
Recent Prices &
|Five Prime Therapeutics||FPRX|
|Price data from Quandl as of most recent close.|
The 14 stocks included in the portfolio
computations are: AMGN, AZN, BMY, CELG, CLDX, CGEN, CRIS, GILD, INCY, MRK, NKTR, NVS, PFE and ZIOP. The current value of the portfolio assumes that $714.29 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 9 stocks excluded from the portfolio computations because of insufficient price data are: BGNE, BLCM, BLUE, CLLS, CYAD, CLVS, CTMX, FPRX and NK.
To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $47,226. The percent return is 372.26%. The annualized return is 16.79%.
|Return Summary for Cancer Immunotherapy Stocks|
|Current Value of Investment||$47,225.64|
|Number Profitable Returns||6,159|
|Percent Profitable Returns||84.83%|
|Number Unprofitable Returns||1,101|
|Percent Unprofitable Returns||15.17%|
|Profitable to Unprofitable Returns Ratio||5.59|
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.